Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Revenio Group Oyj Director's Dealing 2016

Dec 1, 2016

3236_rns_2016-12-01_5474d317-5b72-42c7-a303-5a503d27e243.html

Director's Dealing

Open in viewer

Opens in your device viewer

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation: Managers' transactions

December 1, 2016 at 09:05

Person subject to the notification requirement

Name: Bocap Investment Oy Legal Person

Position: Closely associated person

Person discharging managerial responsibilities in issuer

Name: Kakkonen, Kyösti

Position: Member of the Board/Deputy member


Initial Notification

Reference number: 743700I27E0FWSXLKK04_20161130130506_5


Issuer

Name: Revenio Group Oyj

LEI: 743700I27E0FWSXLKK04


Transaction details

Transaction date: 2016-11-28

Venue: NASDAQ HELSINKI LTD (XHEL)

Nature of the transaction: Disposal

Instrument: Share

ISIN: FI0009010912

Volume: 4800

Unit price: 25.49000 Euro

Aggregated transactions

Volume: 4800

Volume weighted average price: 25.49000 Euro

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

DISTRIBUTION:

Nasdaq Helsinki

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.

[]